Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Kite Pharma Part 4: A Preview of Highly Anticipated Results from Interim Look at ZUMA-1 (KITE, Avoid, $54.95)

Key Points:

I think that an imminent press release dealing with topline results from an interim look at the ZUMA-1…
Read more…